文献速递系统性红斑狼疮其他结缔组织病

糖皮质激素与环磷酰胺对男性系统性红斑狼疮或系统性硬化症患者性激素谱的影响

Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2017-05-04

该研究分析了男性系统性红斑狼疮(SLE)和系统性硬化症(SSc)患者的性激素水平,并与年龄匹配的男性对照比较,探讨糖皮质激素和环磷酰胺(CYC)的影响。结果显示男性SLE患者促黄体生成素(LH)更高且生物活性睾酮缺乏更常见,泼尼松龙日剂量与生物活性睾酮呈负相关;男性SSc患者睾酮和生物活性睾酮显著低于对照;过去一年使用CYC与两组患者生物活性睾酮降低相关。

要点

  • 男性SLE患者LH升高且生物活性睾酮缺乏更常见。
  • 泼尼松龙日剂量与生物活性睾酮水平呈负相关。
  • 过去一年使用CYC与SLE和SSc患者生物活性睾酮降低相关。

核心结论

  • 糖皮质激素对男性SLE患者的性腺功能有负面影响。
  • 研究纳入前一年内使用CYC可损害男性SLE或SSc患者的生物活性睾酮水平。
  • 医生应更关注男性自身免疫病患者发生性腺功能减退的可能性。

研究设计与样本

  • 研究测量了男性SLE患者(n=71)和SSc患者(n=29)空腹血样本中的性激素水平,并与基于人群的年龄匹配男性对照比较。
  • 采用聚类分析识别相关激素谱。

主要发现

  • 男性SLE患者LH水平高于匹配对照(P < 0.0001),生物活性睾酮缺乏更频繁(P = 0.02)。
  • 当前泼尼松龙剂量与生物活性睾酮水平呈负相关(r = -0.36,P = 0.03)。
  • 聚类分析识别出部分SLE患者卵泡刺激素、LH和催乳素升高且生物活性睾酮降低(P < 0.0001),与较高的每日泼尼松龙剂量相关。
  • 男性SSc患者睾酮(P = 0.03)和生物活性睾酮(P = 0.02)显著低于匹配对照。
  • 年龄校正后,过去一年使用CYC与SLE患者(P = 0.02)和SSc患者(P = 0.01)较低的生物活性睾酮水平相关。

临床怎么用

  • 对男性SLE或SSc患者,尤其使用糖皮质激素或近期使用CYC者,应警惕性腺功能减退。
  • 男性SLE患者使用泼尼松龙时需关注生物活性睾酮水平变化。
  • 男性SSc患者应监测睾酮水平。
  • 激素补充治疗的必要性尚需在这些患者中正式评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are autoimmune diseases that predominantly affect female patients, and therefore fewer investigations have been conducted in men. The aim of this study was to analyze sex hormone levels in male patients with SLE and those with SSc, compared to matched controls, in relation to the use of corticosteroids and cyclophosphamide (CYC). METHODS: Sex hormone levels were measured in fasting blood samples from male patients with SLE (n = 71) and those with SSc (n = 29) and compared to population-based, age-matched male controls. Relevant hormone profiles were identified using cluster analysis. RESULTS: Male SLE patients had higher levels of luteinizing hormone (LH) (P < 0.0001) and more frequent bioactive testosterone deficiency (P = 0.02) than their matched controls. The current dosage of prednisolone correlated inversely with the levels of bioactive testosterone (r = -0.36, P = 0.03). Cluster analysis identified a subset of SLE patients with increased levels of follicle-stimulating hormone, LH, and prolactin as well as lower levels of bioactive testosterone (P < 0.0001) in relation to higher daily doses of prednisolone. In male SSc patients, levels of testosterone (P = 0.03) and bioactive testosterone (P = 0.02) were significantly lower than those in matched controls. Use of CYC during the previous year was associated with lower bioactive testosterone levels in both SLE patients (P = 0.02) and SSc patients (P = 0.01), after adjustment for age. CONCLUSION: The results of this study highlight the negative impact of corticosteroids on gonadal function in men with SLE. Furthermore, use of CYC during the year prior to study inclusion impaired bioactive testosterone levels in male patients with either SLE or SSc. Physicians should be more aware of the possibility of hypogonadism in male patients with autoimmune diseases. The need for hormonal supplementation remains to be formally evaluated in these patients.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Arnaud L, Nordin A, Lundholm H, et al. Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. Arthritis Rheumatol. 2017. PMID: 28141919. doi:10.1002/art.40057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。